Résultats de recherche

Retour
1 - 10 de 211 Résultats de recherche
 -  12 Octobre 2018

 -  12 Octobre 2018

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress

Paris (France), 12 October 2018 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that cabozantinib (Cabometyx®), irinotecan liposome injection (Onivyde®), lanreotide (Somatuline®) and the combination of lanreotide and telotristat (Xermelo®) a...

 -  29 Mai 2018

 -  29 Mai 2018

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

...

 -  29 Mai 2018

 -  29 Mai 2018

Ipsen et le MD Anderson concluent un accord de partenariat pour le développement, du laboratoire au chevet du patient, d’un médicament contre le cancer

...

 -  04 Juillet 2018

 -  04 Juillet 2018

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

...

 -  25 Février 2019

 -  25 Février 2019

Ipsen annonce l’acquisition de Clementia Pharmaceuticals et renforce son portefeuille dans les Maladies Rares

Pièce jointe...

 -  26 Juillet 2018

 -  26 Juillet 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

Attachment...

 -  13 Mars 2018

 -  13 Mars 2018

Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team

...

 -  29 Mai 2018

 -  29 Mai 2018

Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer

...

 -  16 Janvier 2018

 -  16 Janvier 2018

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

...

 -  16 Janvier 2018

 -  16 Janvier 2018

Ipsen announces 13 posters and 1 oral presentation at the 2018 ASCO Gastrointestinal Symposium

...

1 … 19 20 21 22